AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE - Generic Drug Details

What are the generic drug sources for amoxicillin; clarithromycin; vonoprazan fumarate and what is the scope of freedom to operate?

Amoxicillin; clarithromycin; vonoprazan fumarate is the generic ingredient in one branded drug marketed by Phathom and is included in one NDA. There are two patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amoxicillin; clarithromycin; vonoprazan fumarate has one hundred and three patent family members in forty-three countries.

One supplier is listed for this compound.

Summary for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

International Patents:	103
US Patents:	2
Tradenames:	1
Applicants:	1
NDAs:	1
Finished Product Suppliers / Packagers:	1
Clinical Trials:	3
DailyMed Link:	AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE at DailyMed

DrugPatentWatch^® Estimated Loss of Exclusivity (LOE) Date for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Constraining patent/regulatory exclusivity:

GENERATING ANTIBIOTIC INCENTIVES NOW

Dosage:

CAPSULE, TABLET, TABLET;ORAL

^*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Tanta University	PHASE2
The First Affiliated Hospital with Nanjing Medical University	Phase 4
Maternity and Child Care Health Center of Dezhou	Phase 4

See all AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE clinical trials

Anatomical Therapeutic Chemical (ATC) Classes for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

A02BC	Proton pump inhibitors
A02B	DRUGS FOR PEPTIC ULCER AND GASTRO-OESOPHAGEAL REFLUX DISEASE (GORD)
A02	DRUGS FOR ACID RELATED DISORDERS
A	Alimentary tract and metabolism

J01CA	Penicillins with extended spectrum
J01C	BETA-LACTAM ANTIBACTERIALS, PENICILLINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

J01FA	Macrolides
J01F	MACROLIDES, LINCOSAMIDES AND STREPTOGRAMINS
J01	ANTIBACTERIALS FOR SYSTEMIC USE
J	Antiinfectives for systemic use

US Patents and Regulatory Information for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes				Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes			Y
Phathom	VOQUEZNA TRIPLE PAK	amoxicillin; clarithromycin; vonoprazan fumarate	CAPSULE, TABLET, TABLET;ORAL	215152-001	May 3, 2022		RX	Yes	Yes

International Patents for AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE

Country	Patent Number	Title	Estimated Expiration
Morocco	29773
European Patent Office	1919865
South Korea	20110042334	PHARMACEUTICAL COMPOSITION
Serbia	52473
Japan	2011529445

AMOXICILLIN; CLARITHROMYCIN; VONOPRAZAN FUMARATE Market Analysis and Financial Projection

Last updated: February 15, 2026

What are the current market dynamics for amoxicillin, clarithromycin, and vonoprazan fumarate?

Amoxicillin

Amoxicillin remains a standard broad-spectrum penicillin antibiotic. Its global market is driven by high prevalence of bacterial infections such as respiratory tract infections, urinary tract infections, and Helicobacter pylori-related gastric conditions. The drug's market is characterized by widespread generic availability, low manufacturing costs, and extensive use in antibiotics stewardship programs.

The global amoxicillin market was valued at approximately $3.2 billion in 2021. It is projected to grow at a compound annual growth rate (CAGR) of 2.5%-3.0% through 2027, led by increasing outpatient prescriptions in developed markets and expanding use in pediatric populations. Concerns related to antibiotic resistance, however, threaten long-term growth sustainability.

Clarithromycin

Clarithromycin, a macrolide antibiotic, is primarily prescribed for respiratory infections, Helicobacter pylori eradication, and mycobacterial diseases. Its market is impacted by rising resistance rates, particularly in respiratory pathogens, leading to decreased usage in some regions.

The global clarithromycin market was valued around $1.4 billion in 2021. Growth prospects are limited by resistance challenges, with an estimated CAGR of approximately 1.5% up to 2026. The drug faces competition from newer antibiotics with better resistance profiles.

Vonoprazan Fumarate

Vonoprazan fumarate is a potassium-competitive acid blocker (P-CAB) approved primarily in Japan. It is used for acid-related gastrointestinal diseases such as gastric ulcers, GERD, and Helicobacter pylori infection. Its market penetration is limited geographically but expanding.

The Japanese vonoprazan fumarate market was valued at about $350 million in 2022. It shows higher growth potential due to increasing acceptance as an alternative to proton pump inhibitors (PPIs), with a projected CAGR of 10% between 2022-2028.

How do competitive forces and regulatory factors influence these drugs' trajectories?

Amoxicillin

The presence of numerous generics reduces prices and profit margins. Regulatory agencies emphasize antibiotic stewardship, limiting overuse. Resistance development and shortages due to manufacturing issues can disrupt supply. Costs for compliance and quality standards are stable but high for manufacturers.

Clarithromycin

Intense competition from newer macrolides and azalides, alongside resistance issues, limit growth. Regulatory agencies restrict use in certain infections to curb resistance. Patent expiries in various regions have driven generic competition, suppressing prices.

Vonoprazan Fumarate

As a newer agent approved in Japan, vonoprazan faces minimal generic competition. Regulatory approval barriers in other markets delay expansion. Patent protection is active, with exclusivity allowing premium pricing. Its safety profile attracts prescribers seeking alternatives to PPIs.

What are the financial forecasts and growth opportunities?

Drug	2021 Market Value	Projected CAGR (2022–2028)	2028 Market Estimate	Key Growth Opportunities	Key Challenges
Amoxicillin	$3.2 billion	2.5% – 3.0%	$4.0 billion	Emerging markets, pediatric use	Resistance, stewardship policies
Clarithromycin	$1.4 billion	1.5% – 2.0%	$1.7 billion	Better resistance management, combination therapies	Resistance, generic price erosion
Vonoprazan Fumarate	$350 million	10% (2022–2028)	$700 million	Expansion beyond Japan, combination regimens	Regulatory approval delays, market penetration

Drivers for growth

• Amoxicillin: Increased use in outpatient settings, rising healthcare access in emerging markets.
• Clarithromycin: New combination therapies for resistant H. pylori strains, updated clinical guidelines.
• Vonoprazan fumarate: Greater recognition as an alternative to PPIs, clinical trials validating efficacy.

What market factors could reshape these trajectories?

1. Antibiotic resistance:

Amoxicillin and clarithromycin face resistance-driven decline. New formulations or resistant-variant targeting agents could influence future sales.

2. Regulatory environment:

Antibiotic stewardship programs and restrictions limit overuse, restricting sales growth. Approval pathways in North America and Europe for vonoprazan could alter market size.

3. Patent and generic expiration:

Coverage of patent expirations affects pricing and margins. Amoxicillin generics dominate large segments.

4. Emerging markets:

Growing healthcare infrastructure enhances access, but pricing pressures may slow revenue growth.

5. New drug developments:

Innovative therapies with superior resistance profiles or targeted delivery systems could displace existing drugs.

Key Takeaways

• Amoxicillin's global market is stable but faces resistance challenges that restrict longer-term expansion.
• Clarithromycin's growth is impeded primarily by increasing resistance and generic competition.
• Vonoprazan fumarate exhibits the highest growth potential among the three, mainly in Japan, with prospects for global expansion contingent on regulatory approvals.
• Competitive pressures, resistance development, and regulatory policies are primary influences on market trajectories.
• Growth opportunities hinge on expanding indications, geographical penetration, and resistance management strategies.

FAQs

1. How will antibiotic resistance affect amoxicillin’s future sales?
Resistance limits antibiotic effectiveness, leading to decreased prescriptions. Innovations or combination therapies may mitigate this but generally pose long-term risks to volume growth.

2. Will clarithromycin maintain its market share?
Resistance reduces its efficacy in several infections, pushing clinicians toward alternative agents. Its market share is likely to decline unless new formulations or indications emerge.

3. What are the prospects for vonoprazan fumarate outside Japan?
Limited approval outside Japan restricts sales. Regulatory attribution, clinical validation, and market acceptance are essential for global growth.

4. How significant are patent expirations for these drugs?
Amoxicillin and clarithromycin face generic competition, which lowers prices and margins significantly. Vonoprazan’s patent status influences its premium positioning.

5. What are the main factors driving vonoprazan fumarate’s growth?
Its efficacy as an alternative to PPIs, expanding clinical trials, and potential approval in new markets are primary drivers.

---

Sources:
[1] MarketResearch.com, "Global Antibiotics Market," 2022.
[2] Grand View Research, "Proton Pump Inhibitors Market," 2022.
[3] IQVIA Reports, "Global Pharmaceutical Market Trends," 2022.